• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes.变革癌症治疗：利用生物标志物的力量改善患者预后。
J Adv Pract Oncol. 2023 Apr;14(Suppl 1):4-8. doi: 10.6004/jadpro.2023.14.3.15. Epub 2023 Apr 1.
2
Staying Abreast of New Biomarkers in Hematology/Oncology.紧跟血液学/肿瘤学领域的新型生物标志物发展动态
J Adv Pract Oncol. 2024 Apr;15(3):164-169. doi: 10.6004/jadpro.2024.15.3.2. Epub 2024 Apr 1.
3
The Role of Biomarkers in Guiding Clinical Decision-Making in Oncology.生物标志物在肿瘤学临床决策指导中的作用。
J Adv Pract Oncol. 2023 Apr;14(Suppl 1):15-37. doi: 10.6004/jadpro.2023.14.3.17. Epub 2023 Apr 1.
4
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?从患者权益倡导者的角度来看：癌症免疫疗法是否代表了一种范式转变？
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
5
Precision oncology for breast cancer through clinical trials.通过临床试验实现乳腺癌的精准肿瘤学。
Clin Exp Metastasis. 2022 Feb;39(1):71-78. doi: 10.1007/s10585-021-10092-0. Epub 2021 May 5.
6
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.系统评价靶向或免疫治疗联合治疗晚期实体瘤。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002459.
7
Novel and Expanded Oncology Drug Approvals of 2016-PART 1: New Options in Solid Tumor Management.2016年新型及扩展型肿瘤药物批准情况——第1部分：实体瘤治疗新选择
Oncology (Williston Park). 2017 Feb 15;31(2):110-21.
8
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.程序性死亡配体 1（PD-L1）表达作为预测生物标志物的作用：对所有美国食品和药物管理局（FDA）批准的免疫检查点抑制剂的分析。
J Immunother Cancer. 2019 Oct 26;7(1):278. doi: 10.1186/s40425-019-0768-9.
9
Biomarkers for checkpoint inhibition in hematologic malignancies.血液恶性肿瘤中检查点抑制的生物标志物。
Semin Cancer Biol. 2018 Oct;52(Pt 2):198-206. doi: 10.1016/j.semcancer.2018.05.005. Epub 2018 Jun 18.
10
The FDA Oncology Center of Excellence and precision medicine.美国食品和药物管理局肿瘤卓越中心与精准医学
Exp Biol Med (Maywood). 2018 Feb;243(3):308-312. doi: 10.1177/1535370217740861. Epub 2017 Nov 6.

引用本文的文献

1
Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer.嵌合抗原受体（CAR）-NK92细胞在体外以及卵巢癌小鼠异种移植模型中对胶质母细胞瘤、乳腺癌和胰腺癌有效。
Cancer Cell Int. 2025 Jul 11;25(1):260. doi: 10.1186/s12935-025-03865-0.
2
Fertility-sparing surgery upon reproductive and oncologic results in ovarian cancer patients stage I (FIGO): a systematic review.I期（国际妇产科联盟）卵巢癌患者保留生育功能手术对生殖及肿瘤学结局的影响：一项系统评价
Arch Gynecol Obstet. 2025 May 23. doi: 10.1007/s00404-025-08062-y.
3
FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies: A Systematic Review.FGFR作为胃肠道恶性肿瘤靶向治疗的预测标志物：一项系统综述
J Gastrointest Cancer. 2025 Apr 9;56(1):96. doi: 10.1007/s12029-025-01214-y.
4
Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations.癌症生物标志物与精准肿瘤学：近期趋势与创新综述
Clin Med Insights Oncol. 2024 Nov 17;18:11795549241298541. doi: 10.1177/11795549241298541. eCollection 2024.
5
Therapeutic targeting of voltage-gated sodium channel Na1.7 for cancer metastasis.针对电压门控钠通道Na1.7进行癌症转移的治疗靶向研究。
Front Pharmacol. 2024 Jul 9;15:1416705. doi: 10.3389/fphar.2024.1416705. eCollection 2024.
6
MiR-320a upregulation contributes to the effectiveness of pemetrexed by inhibiting the growth and invasion of human lung cancer cell line (Calu-6).miR-320a 的上调通过抑制人肺癌细胞系（Calu-6）的生长和侵袭来提高培美曲塞的疗效。
Mol Biol Rep. 2024 Feb 19;51(1):310. doi: 10.1007/s11033-024-09207-z.

本文引用的文献

1
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.错配修复和微卫星不稳定性检测用于免疫检查点抑制剂治疗：美国病理学家学会与分子病理学协会和抗击结直肠癌联盟的指南。
Arch Pathol Lab Med. 2022 Oct 1;146(10):1194-1210. doi: 10.5858/arpa.2021-0632-CP.
2
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.十年后的免疫检查点抑制剂：基础研究与临床应用在癌症免疫治疗中的贡献
Immune Netw. 2022 Feb 14;22(1):e2. doi: 10.4110/in.2022.22.e2. eCollection 2022 Feb.
3
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.美国食品药品监督管理局批准概要：卡马替尼和特泊替尼用于治疗携带 MET 外显子 14 跳跃突变或改变的转移性非小细胞肺癌。
Clin Cancer Res. 2022 Jan 15;28(2):249-254. doi: 10.1158/1078-0432.CCR-21-1566. Epub 2021 Aug 3.
4
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.可用药靶点与致癌驱动因素相遇：基于靶点的肿瘤分类的机会和局限性，以及分子肿瘤委员会的作用。
ESMO Open. 2021 Apr;6(2):100040. doi: 10.1016/j.esmoop.2020.100040. Epub 2021 Feb 2.
5
The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.NCI-MATCH：一项针对多种肿瘤组织学类型的全国性协作精准肿瘤学试验。
Cancer Cell. 2021 Jan 11;39(1):22-24. doi: 10.1016/j.ccell.2020.12.021.
6
FDA Approval Summary: Entrectinib for the Treatment of gene Fusion Solid Tumors.FDA 批准概要：恩曲替尼治疗基因融合型实体瘤。
Clin Cancer Res. 2021 Feb 15;27(4):928-932. doi: 10.1158/1078-0432.CCR-20-2771. Epub 2020 Sep 23.
7
Tazemetostat: First Approval.他泽莫司他：美国首次批准
Drugs. 2020 Apr;80(5):513-521. doi: 10.1007/s40265-020-01288-x.
8
Site-agnostic biomarker-guided oncology drug development.基于无靶点生物标志物的肿瘤药物研发。
Expert Rev Mol Diagn. 2020 Jun;20(6):583-592. doi: 10.1080/14737159.2020.1702521. Epub 2019 Dec 12.
9
Precision Medicine in Oncology Pharmacy Practice.肿瘤药学实践中的精准医学
Acta Med Acad. 2019 Apr;48(1):90-104. doi: 10.5644/ama2006-124.246.
10
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.复发性子宫内膜癌的全面基因组分析：对系统治疗选择的影响。
Gynecol Oncol. 2019 Sep;154(3):461-466. doi: 10.1016/j.ygyno.2019.06.016. Epub 2019 Jun 27.

变革癌症治疗：利用生物标志物的力量改善患者预后。

Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes.

作者信息

Moore Donald C, Guinigundo Andrew S

机构信息

From Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.

Cincinnati Cancer Advisors, Cincinnati, Ohio.

出版信息

J Adv Pract Oncol. 2023 Apr;14(Suppl 1):4-8. doi: 10.6004/jadpro.2023.14.3.15. Epub 2023 Apr 1.

DOI:10.6004/jadpro.2023.14.3.15
PMID:37206906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10190803/
Abstract

There has been an increasing number of approvals for targeted therapies and immunotherapies in oncology in the past decade. This has changed the treatment paradigm for many solid tumors and hematologic malignancies, and therefore the outcomes of patients with cancer. Advanced practitioners should be up to date with advances in cancer biomarker testing and its implications for the use of targeted therapy and immunotherapy to integrate this information into clinical decision-making.

摘要

在过去十年中，肿瘤学领域针对靶向治疗和免疫治疗的批准数量不断增加。这改变了许多实体瘤和血液系统恶性肿瘤的治疗模式，进而改变了癌症患者的治疗结局。高级从业者应跟上癌症生物标志物检测的进展及其对靶向治疗和免疫治疗应用的影响，以便将这些信息整合到临床决策中。